Skip to main content

Methylprednisolone Acetate Injection Shortage

Last Updated: June 27, 2017
Status: Resolved

Products Affected - Description
    • Methylprednisolone Acetate injection, Sandoz, 40 mg/mL, 1 mL vial, 1 count, NDC 00781-3131-71
    • Methylprednisolone Acetate injection, Sandoz, 40 mg/mL, 1 mL vial, 10 count, NDC 00781-3131-95
    • Methylprednisolone Acetate injection, Sandoz, 40 mg/mL, 10 mL vial, 1 count, NDC 00781-3136-70
    • Methylprednisolone Acetate injection, Sandoz, 80 mg/mL, 1 mL vial, 1 count, NDC 00781-3132-71
    • Methylprednisolone Acetate injection, Sandoz, 80 mg/mL, 1 mL vial, 10 count, NDC 00781-3132-95
    • Methylprednisolone Acetate injection, Sandoz, 80 mg/mL, 5 mL vial, 1 count, NDC 00781-3137-75
Reason for the Shortage
    • Sandoz could not provide a reason for the shortage.
    • Pfizer had Depo-Medrol injection on a short-term shortage due to increased demand of Solu-Medrol.
    • Teva is not actively marketing methylprednisolone acetate.
Available Products
    • Depo-Medrol injection, Pfizer, 20 mg/mL, 5 mL vial, 1 count, NDC 00009-0274-01
    • Depo-Medrol injection, Pfizer, 40 mg/mL, 1 mL vial, 1 count, NDC 00009-3073-01
    • Depo-Medrol injection, Pfizer, 40 mg/mL, 1 mL vial, 25 count, NDC 00009-3073-03
    • Depo-Medrol injection, Pfizer, 40 mg/mL, 10 mL vial, 1 count, NDC 00009-0280-03
    • Depo-Medrol injection, Pfizer, 40 mg/mL, 10 mL vial, 25 count, NDC 00009-0280-52
    • Depo-Medrol injection, Pfizer, 40 mg/mL, 5 mL vial, 1 count, NDC 00009-0280-02
    • Depo-Medrol injection, Pfizer, 40 mg/mL, 5 mL vial, 25 count, NDC 00009-0280-51
    • Depo-Medrol injection, Pfizer, 80 mg/mL, 1 mL vial, 1 count, NDC 00009-3475-01
    • Depo-Medrol injection, Pfizer, 80 mg/mL, 1 mL vial, 25 count, NDC 00009-3475-03
    • Depo-Medrol injection, Pfizer, 80 mg/mL, 5 mL vial, 1 count, NDC 00009-0306-02
    • Depo-Medrol injection, Pfizer, 80 mg/mL, 5 mL vial, 25 count, NDC 00009-0306-12

Estimated Resupply Dates

    • Sandoz has methylprednisolone acetate injection temporarily unavailable and the company cannot estimate a release date.

Implications for Patient Care

    • FDA closed New England Compounding Company in Massachusetts due to a fungal meningitis outbreak linked to methylprednisolone acetate injections compounded by this pharmacy. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm322849.htm?source=govdelivery.
    • All commercially available products contain a preservative such as myristyl gamma picolinium chloride or benzyl alcohol.
    • Methylprednisolone acetate is not approved for epidural administration and contraindicated for intrathecal use.

Updated

Updated June 27, 2017 by Leslie Jensen, PharmD, Drug Information Specialist. Created May 22, 2012 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer